Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation

Open access article

Abstract:

"Cisplatin is the most common antineoplastic drug used for the therapy

 of solid tumours. To date, researchers have focused on the dosage to

 be administered for each specific tumour, mainly considering the local

 adverse effects. The aim of this study was to correlate the severity of

 the adverse effects with: i) the dosage of cisplatin; ii) the specific

 site of the tumour; iii) the association with other drugs; and iv) the

 symptoms. We analysed data from 123 patients with 11 different

 tumour classes undergoing therapy from 2007 to 2008

 at St. Anna Hospital (Ferrara, Italy), using the Spearman

 non-parametric correlation index. Even though significant correlations

 were found among the variables, the overall results showed that the 

 main factor influencing the severity of the adverse effects was the

 dosage of cisplatin administered......

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered. - See more at: http://www.spandidos-publications.com/or/29/4/1285#sthash.QxOJrWcd.dpu

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered. - See more at: http://www.spandidos-publications.com/or/29/4/1285#sthash.QxOJrWcd.dpuf

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Authors: Laura Astolfi, Sara Ghiselli, Valeria Guaran, Milvia Chicca, Edi Simoni, Elena Olivetto, Giorgio Lelli, Alessandro Martini
Affiliations: Bioacoustics Research Laboratory, University of Padua, I-35129 Padua, Italy, ENT Surgery, Department of Neurosciences, University of Padua, I-35129 Padua, Italy, Department of Life Sciences and Biotechnology, University of Ferrara, I-44121 Ferrara, Italy, Clinical Oncology Unit, St. Anna University-Hospital, I-44121 Ferrara, Italy
Published online on: Wednesday, February 6, 2013
Doi: 10.3892/or.2013.2279
Pages: 1285-1292
Abstract:

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered.

OPEN ACCESS ARTICLE

- See more at: http://www.spandidos-publications.com/or/29/4/1285#sthash.QxOJrWcd.dpuf

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Authors: Laura Astolfi, Sara Ghiselli, Valeria Guaran, Milvia Chicca, Edi Simoni, Elena Olivetto, Giorgio Lelli, Alessandro Martini
Affiliations: Bioacoustics Research Laboratory, University of Padua, I-35129 Padua, Italy, ENT Surgery, Department of Neurosciences, University of Padua, I-35129 Padua, Italy, Department of Life Sciences and Biotechnology, University of Ferrara, I-44121 Ferrara, Italy, Clinical Oncology Unit, St. Anna University-Hospital, I-44121 Ferrara, Italy
Published online on: Wednesday, February 6, 2013
Doi: 10.3892/or.2013.2279
Pages: 1285-1292
Abstract:

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered.

OPEN ACCESS ARTICLE

- See more at: http://www.spandidos-publications.com/or/29/4/1285#sthash.QxOJrWcd.dpuf

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Authors: Laura Astolfi, Sara Ghiselli, Valeria Guaran, Milvia Chicca, Edi Simoni, Elena Olivetto, Giorgio Lelli, Alessandro Martini
Affiliations: Bioacoustics Research Laboratory, University of Padua, I-35129 Padua, Italy, ENT Surgery, Department of Neurosciences, University of Padua, I-35129 Padua, Italy, Department of Life Sciences and Biotechnology, University of Ferrara, I-44121 Ferrara, Italy, Clinical Oncology Unit, St. Anna University-Hospital, I-44121 Ferrara, Italy
Published online on: Wednesday, February 6, 2013
Doi: 10.3892/or.2013.2279
Pages: 1285-1292
Abstract:

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered.

OPEN ACCESS ARTICLE

- See more at: http://www.spandidos-publications.com/or/29/4/1285#sthash.QxOJrWcd.dpuf

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Authors: Laura Astolfi, Sara Ghiselli, Valeria Guaran, Milvia Chicca, Edi Simoni, Elena Olivetto, Giorgio Lelli, Alessandro Martini
Affiliations: Bioacoustics Research Laboratory, University of Padua, I-35129 Padua, Italy, ENT Surgery, Department of Neurosciences, University of Padua, I-35129 Padua, Italy, Department of Life Sciences and Biotechnology, University of Ferrara, I-44121 Ferrara, Italy, Clinical Oncology Unit, St. Anna University-Hospital, I-44121 Ferrara, Italy
Published online on: Wednesday, February 6, 2013
Doi: 10.3892/or.2013.2279
Pages: 1285-1292
Abstract:

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered.

OPEN ACCESS ARTICLE

- See more at: http://www.spandidos-publications.com/or/29/4/1285#sthash.QxOJrWcd.dpuf